BIV Vanguard Intermediate Term Bond

Forum Alert: Bioenvision Inc. Presentation at Informed Investors Biotechnology & Pharmaceuticals Stocks Forum at the Princeton Club in NYC on Wednesday, June 23, 2004, 12:30 pm ET NEW YORK, June 21 /PRNewswire/ -- Dr. Chris Wood, Chairman & Chief Executive Officer of Bioenvision Inc. (AMEX:BIV), will present at the following forum: What: Informed Investors Biotechnology & Pharmaceuticals Stocks Forum When: June 23, 2004 @ 12:30 PM Eastern Time Where: The Princeton Club of New York, 15 West 43rd St. (Between 5th and 6th Avenues) New York, NY 10036 How: To attend live event, pre-registration is necessary. To register contact Cary Loeser, , 804-327-3407 or call Customer Service at 888-301-6618. If you are unable to attend the live event, the forum will be available via webcast at http://www.informedinvestors.com/CustomEvent/85117/index.asp?ForumID=85117. Bioenvision Inc. is an emerging biopharmaceutical company whose primary business focus is the development and distribution of drugs to treat cancer. The Company has a broad range of products and technologies under development, but its two lead drugs are Clofarabine and Modrenal. Clofarabine is up for approval in the U.S. for the treatment of pediatric acute leukemias and will be submitted for approval in Europe in the near term. Clofarabine has demonstrated efficacy in several other commercially significant cancer indications and management believes this drug could achieve blockbuster status. Modrenal is approved for marketing in the United Kingdom for advanced breast cancer. The Company's has taken Modrenal into the United States to perform further clinical trials, initially, in prostate cancer and, in the longer term, breast cancer. Most of the Company's other drugs are now in clinical trials in various stages of development. Bioenvision is developing products for a wide range of solid tumors (including breast, prostate, colorectal, pancreatic and bladder) and hematologic malignancies (including acute myeloid leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia and lymphoma). FORUM CONTACT: Cary Loeser, Informed Investors, 804-327-3407, Web site: http://www.informedinvestors.com DATASOURCE: Bioenvision Inc. CONTACT: Cary Loeser of Informed Investors, +1-804-327-3407, or , for Bioenvision Inc. Web site: http://www.informedinvestors.com/

Copyright